<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01642524</url>
  </required_header>
  <id_info>
    <org_study_id>TOPHR HIT</org_study_id>
    <nct_id>NCT01642524</nct_id>
  </id_info>
  <brief_title>The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial (TOPHR HIT)</brief_title>
  <acronym>TOPHR HIT</acronym>
  <official_title>The Toronto Prehospital Hypertonic Resuscitation-Head Injury and Multi Organ Dysfunction Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Defence Research and Development Canada</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TOPHR HIT trial is a clinical trial of patients experiencing blunt trauma who present&#xD;
      with an injury to their head which makes them unconscios. The study compares two different&#xD;
      fluids given to the patient in the out of hospital setting by a paramedic. The two fluids are&#xD;
      salt water (standard treatment) versus a higher concentration of salt water mixed with a&#xD;
      sugar (study fluid). The patients have an equal chance of receiving either fluid and the&#xD;
      paramedic and the patient and the treating trauma surgeon do not know which fluid was&#xD;
      provided in the out of hospital setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objective&#xD;
&#xD;
      The primary objective of this study is to report feasibility in accordance with the&#xD;
      methodology described by Lancaster and Dodds, specifically addressing:&#xD;
&#xD;
        1. baseline survival rates for the treatment and control group to aid in the design of a&#xD;
           definitive multicentre trial.&#xD;
&#xD;
        2. randomization compliance rate.&#xD;
&#xD;
        3. ease of protocol implementation in the out-of-hospital setting.&#xD;
&#xD;
        4. adverse rate of Hypertonic Saline Dextran (HSD) infusion.&#xD;
&#xD;
      The secondary objectives include measuring the effect of HSD in modulating the&#xD;
      immuno-inflammatory response to severe head injury and its effect on modulating the release&#xD;
      of neuro-biomarkers into serum; evaluating the role of serum neuro-biomarkers in predicting&#xD;
      patient outcome and clinical response to HSD intervention; evaluating effects of HSD on brain&#xD;
      atrophy post-injury and neurocognitive and neuropsychological outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30 day survival</measure>
    <time_frame>30 days after discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>48 hrs after admission</time_frame>
    <description>•Survival: 48 hours after admission; Hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional neurological outcomes at 4 months</measure>
    <time_frame>4 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological testing at 4 months</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological testing at 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physiologic parameters indicative of organ dysfunction</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structural parameters indicative of brain injury or dysfunction at 4 months</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum inflammatory markers measured on arrival, 12, 24, 48 hours later</measure>
    <time_frame>12, 24, 48 hours later</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>hypertonic saline mixed Dextran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hypertonic saline mixed Dextran</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo controlled</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hypertonic saline mixed Dextran</intervention_name>
    <description>single dose administered intravenously</description>
    <arm_group_label>hypertonic saline mixed Dextran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline solution</intervention_name>
    <description>placebo - saline solution</description>
    <arm_group_label>Placebo controlled</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥16&#xD;
&#xD;
          -  Initial assessment of Glasgow Coma Score (GCS) 8 or less&#xD;
&#xD;
          -  Blunt traumatic mechanism of injury&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known pregnancy&#xD;
&#xD;
          -  Penetrating primary injury&#xD;
&#xD;
          -  VSA prior to randomization; previous intravenous therapy ≥ 50 ml&#xD;
&#xD;
          -  Time interval between arrival at scene and intravenous access exceeds four hours&#xD;
&#xD;
          -  Amputation of above wrist or ankle&#xD;
&#xD;
          -  Any burn (thermal, chemical, electrical, radiation)&#xD;
&#xD;
          -  Suspected hypothermia&#xD;
&#xD;
          -  Asphyxia (strangulation, hanging, choking, suffocation, drowning) and fall from height&#xD;
             ≤ 1m or ≤ 5 stairs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Unity Health Toronto</investigator_affiliation>
    <investigator_full_name>Dr. Laurie Morrison</investigator_full_name>
    <investigator_title>Clinician Scientist</investigator_title>
  </responsible_party>
  <keyword>resuscitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Craniocerebral Trauma</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextrans</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

